The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial
作者： Petar Alaupovic , Wendy J. Mack , Carolyn Knight-Gibson , Howard N. Hodis
关键词:
摘要: Abstract We have demonstrated previously in a subset of Monitored Atherosclerosis Regression Study (MARS) subjects with hypercholesterolemia (190 to 295 mg/dL) and documented coronary artery disease that lovastatin significantly reduces cholesterol-rich lipoprotein B (LpB) but has little effect on complex, triglyceride-rich apolipoprotein (apo) B–containing LpBc (the sum LpB:C, LpB:C:E LpA-II:B:C:D:E) particles defined by their composition. This differential apoB-containing families offered the opportunity determine same MARS independent relationship LpB progression disease. Subjects randomized either (40 mg twice daily) or matching placebo were evaluated angiography before randomization after 2 years treatment, overall status was judged global change score. In lovastatin-treated group, there 22 nonprogre...
sci-hub.se 参考文章(63)
Robert D. Leachman, Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4 Texas Heart Institute Journal. ,vol. 21, pp. 179- 179 ,(1994)
R Havel, McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis--new perspectives. The American Journal of Clinical Nutrition. ,vol. 59, pp. 795- 796 ,(1994) , 10.1093/AJCN/59.4.795
William Hollander, Marilyn Colombo, John Pad dock, Lipoproteins in human atherosclerotic vessels Experimental and Molecular Pathology. ,vol. 30, pp. 172- 189 ,(1979) , 10.1016/0014-4800(79)90052-2
MELISSA A. AUSTIN, Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. American Journal of Epidemiology. ,vol. 129, pp. 249- 259 ,(1989) , 10.1093/OXFORDJOURNALS.AJE.A115130
J.M. Bard, H.J. Parra, P. Douste-Blazy, J.C. Fruchart, Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. Metabolism-clinical and Experimental. ,vol. 39, pp. 269- 273 ,(1990) , 10.1016/0026-0495(90)90046-F
R.F. Atmeh, J. Shepherd, C.J. Packard, Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochimica et Biophysica Acta. ,vol. 751, pp. 175- 188 ,(1983) , 10.1016/0005-2760(83)90172-8
Claes-Henrik Florén, John J. Albers, Edwin L. Bierman, Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cellS Biochimica et Biophysica Acta. ,vol. 663, pp. 336- 349 ,(1981) , 10.1016/0005-2760(81)90219-8
D B Zilversmit, Atherogenesis: a postprandial phenomenon. Circulation. ,vol. 60, pp. 473- 485 ,(1979) , 10.1161/01.CIR.60.3.473
T. O’Brien, T. T. Nguyen, B. J. Hallaway, D. Hodge, K. Bailey, D. Holmes, B. A. Kottke, The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 15, pp. 228- 231 ,(1995) , 10.1161/01.ATV.15.2.228
Daniel Steinberg, Lipoproteins and Atherogenesis JAMA. ,vol. 264, pp. 3047- 3052 ,(1990) , 10.1001/JAMA.1990.03450230083034